Abstract: This invention relates to a biological activator for a septic tank of the type comprising a product in the form of solid particles, which is non-corrosive, non-toxic, finely divided, and of large specific area, comprising a colloidal phase in suspension and a flocculent phase, having a reducing power of mineral origin, its function being to form a support for anaerobic microbial flora in a septic tank in order to increase the bacterial saturation density in a septic tank for an equivalent quantity of nutrients, its specific area being (in m2/g) between about 25 and 66, more particularly between about 35 and 66, and advantageously between about 46 and 60, and a cation exchange capacity (in meq/100 g) between about 9 and 38, more particularly between about 14 and 38, and advantageously between about 24 and 35.

Abstract: The invention provides depilatory compositions comprising: (a) a continuous aqueous phase; (b) a depilatory agent; and (c) at phase comprising (i) a non-polar coil separated from the continuous aqueous phase by a bilayer phase comprising (ii) a surfactant; (iii) a polar substance; wherein the composition is substantially free from tertiary amines; processes for their preparation; and their use degrading hair keratin.

Abstract: This invention in general relates to novel pharmaceutical compositions for acid labile substances as well as for methods of making such. Specifically, the invention provides a pharmaceutical composition comprising about 1 to 75% by weight acid labile compound, up to about 5% by weight disintegrant, at least one protector coat layer used to separate and protect the acid labile substance from acid reacting groups and gastric juice, and at least one enteric coat layer which surrounds the protector coating layer and ensures delivery of over 80% the acid labile substance to the small intestine.

Abstract: Quickly disintegratable compression-molded materials containing (a) fillers and (b) erythritol. These materials are highly disintegratable and soluble in the oral cavity or water and, therefore, can be easily taken. Also, they are highly hard and thus excellent in storage stability in the production and distribution stages. Owing to these characteristics, they can be appropriately blended with efficacious ingredients and used in the treatment or prevention of diseases in patients, in particular, the aged, infants or those having difficulty in swallowing.

Abstract: Cosmetic composition comprising particles of melamine-formaldehyde or urea-formaldehyde resin and its uses. The present application relates to a composition comprising, in a physiologically acceptable medium, at least one oily phase and particles of melamine-formaldehyde or urea-formaldehyde resin, to the use of the said composition, especially as a cosmetic composition for caring for and/or making up the skin, in particular for softening defects of the relief of the skin, such as microrelief features, wrinkles or pores, while conferring a natural appearance on the skin, and to its use in treating greasy skin. The particles advantageously have a number-average size ranging from approximately 0.1 to 20 &mgr;m. The composition of the invention can be anhydrous or can be provided in the form of a water-in-oil or oil-in-water emulsion. The invention also relates to the use of particles of melamine-formaldehyde or urea-formaldehyde resin as mattifying agent in a cosmetic composition.

Abstract: The present invention relates to a means for creating a mass having structural integrity, including a rapidly disintegratable tablet for administration with or without the use of water. The present invention has a wide variety of different uses and applications. One embodiment is a tablet intended for oral administration. The tablet comprises at least one active ingredient and a mixture of excipients. The excipients provide desired characteristics and physical properties and when the tablet is sintered or heated, excellent tablet binding characteristics are obtained. The tablet is intended primarily for oral administration and dissolves in the presence of water. Also disclosed is a process for the preparation of a rapidly disintegratable tablet for administration with or without the use of water.

Abstract: Novel pharmaceutical compositions which improve the rate and/or extent of absorption of drugs are disclosed. The novel pharmaceutical compositions of the present invention comprise drug-containing microemulsions adsorbed onto solid particles which may be further formulated into solid dosage forms. The compositions and dosage forms of the present invention improve the bioavailability of a wide range of drugs including drugs that are known or suspected of having poor bioavailability by the utilization of several different mechanisms.

Abstract: A pharmaceutical composition is provided containing an admixture of phenytoin sodium and an erodible matrix which extends the release of the phenytoin sodium over about a two hour period. The erodible matrix comprises binder(s) and diluent(s) which control the release of drug from the pharmaceutical composition. The erodible matrix can further comprise an alkaline pH modifier.

Abstract: A liquid pesticidal composition, which is substantially free of water, comprising a hydrophobic pesticide or mixture of pesticides dissolved in an organic solvent and comprising as surfactants (a) a castor oil ethoxylate having 30-50 mol ethoxylate, (b) a branched C8-C18 alcohol ethoxylate having 5-10 mol ethoxylate, and (c) a tristyrenephenol-ethoxylate having 8-30 mol ethoxylate, or its phosphate or salt thereof. The compositions also include gels having a viscosity of 500 to 20,000 mPas and comprising additionally a gelling agent.

Abstract: This invention relates to a process for the preparation of a controlled release pharmaceutical composition comprising two discrete zones wherein the first discrete zone comprises therapeutically effective amount of pseudoephedrine or its pharmaceutically acceptable salt as active ingredient and the second discrete zone comprises a therapeutically effective amount of a long-acting antihistamine selected from the group consisting of loratadine, azatidine, fexofenadine, terfenadine, cetirizine, astemizole, and levocabastine, or their pharmaceutically acceptable salt as active ingredient.

Abstract: A directly compressible ultra fine acetaminophen granulation composition capable of being directly compressed into an acetaminophen tablet comprises from about 85 to about 95 wt % acetaminophen, from about 1 to about 4 wt % essentially water-insoluble tablet/capsule disintegrant, from about 0.5 to about 5.0 wt % polyvinylpyrrolidone, from about 0.5 to about 5.0 wt % totally pregelatinized starch, about 0.25 to about 3.0 wt % of a fluidizing agent, from about 0.25 to about 3.0 wt % of a lubricant, and optionally up to about 10 wt % of a co-active ingredient, the weight percents being based on the total weight of the dry components of the granulation composition, the granulation also comprising a moisture content of up to about 1.5 wt % based on the total weight of the dry components of granulation composition.

Abstract: This invention relates to a single phase emulsifiable concentrate composition comprising (a) between about 0.05 and about 25 wt. % of a biologically, fungicidally and/or herbicidally active aza compound; (b) between about 2 and about 40 wt. % of a lactam selected from the group of N-methyl pyrrolidone, N-methyl caprolactam, a C8 to C18 alkyl pyrrolidone, a C8 to C18 caprolactam and a mixture thereof; (c) between about 2 and about 20 wt. % of a moisture scavenging agent selected from the group consisting of a liquid molecularly hindered carbodiimide, a molecular sieve or a mixture thereof and (d) between about 10 and about 80 wt. % of a mixture of at least two non-ionic surfactants having an overall hydrophilic/lipophilic balance (HLB) above 7. The invention also relates to the stable oil-in-water (o/w) miniemulsions prepared from the above by dilution to between about 40 and about 99.99 wt. % water for a “pour on”, dip or spray solution useful in the treatment of animals or plants.

Abstract: A process for encapsulation of caplets in a capsule comprises the following steps: a. providing empty capsule parts; b. filling at least one of said capsule parts with one or more caplets; c. putting said capsule parts together; and d. treating the combined parts by cold shrinking. The solid dosage forms obtainable by such a process are tamper-proof in that they cannot be opened in a way to be reassembled without showing such opening process.

Abstract: The invention relates to an effervescent, rapidly disintegrating oral dosage form of (a) an alkali-sensitive active ingredient, (b) an effervescent base comprising at least one of (i) at least one alkaline earth metal carbonate, (ii) an organic edible acid, and (iii) an alkali metal salt of citric acid, and optionally (c) a pharmaceutically acceptable auxiliary ingredient, and to a process for preparing the dosage form.

Abstract: The present invention provides a composition which includes one or more organic suncreens and colloidal silicon dioxide. Preferably, the colloidal silicon dioxide is prewetted with a liquid, such as liquid silicone. In another embodiment, the present invention provides a composition for topical application to the lips or oval cavity. The composition includes a topically applicable anhydrous base; a malflavored organic sunscreen; and a malflavored organic sunscreen taste-masking effective amount of colloidal silicon dioxide. In yet another embodiment, a method of preparing the composition of the present invention is provided. The method includes the steps of (a) mixing silicon dioxide and a liquid, such as silicone; (b) adding the mixture of step (a) to a melted anhydrous base material; (c) adding an organic sunscreen to the mixture of step (b); and (d) cooling the mixture of step (c).

Abstract: A particulate co-processed composition that includes a botanical plant, microcrystalline cellulose and calcium carbonate. The botanical plant is selected from the group consisting of grains, plants, roots, and mixtures thereof. The co-processed composition is particularly useful in the manufacture of vitamins and food supplements. The co-processed composition is prepared by forming a slurry of the botanical plant, microcrystalline cellulose, and calcium carbonate and then drying the slurry to yield a particulate product.

Abstract: A method for preparing solid rapidly disintegrating dosage forms shaped as biconvex tablets having symmetrical top and bottom surfaces and dosage forms obtainable thereby.

Abstract: The present invention relates to a delayed-release pharmaceutical composition which is in the form of tablets prepared by direct tableting and consisting of at least one active principle and a matrix which gives the said composition its delayed-release effect, characterized in that the said matrix consists at least in part of pregranulated polysaccharides of high molecular weight and of synthetic or natural origin.

Abstract: A pharmaceutical composition has a blend of at least first and second components and a medicament in a sufficient amount to be therapeutic where the first component is ethylcellulose (EC) and the second component is at least one other polymer selected from the group consisting of methylcellulose (MC), ethylhydroxyethylcellulose (EHEC), hydroxyethylmethylcellulose (HEMC), hydrophobically modified hydroxyethylcellulose (HMHEC), hydrophobically modified ethylhydroxyethylcellulose (HMEHEC), carboxymethylhydroxyethylcellulose (CMHEC), carboxymethyl hydrophobically modified hydroxyethylcellulose (CMHMHEC), guar, pectin, carrageenan, agar, algin, gellan gum, acacia, starch and modified starches, mono- and co-polymers of carboxyvinyl monomers, mono- and co-polymers of acrylate or methacrylate monomers, mono- and co-polymers of oxyethylene and oxypropylene and mixtures thereof. The medicament can be a variety of drugs or nutritional supplements.

Abstract: A pharmaceutical composition useful for treating ocular conditions, such as glaucoma. In particular, the pharmaceutical composition is a sustained release oral dosage composition for relieving intraocular pressure comprising methazolamide and a high molecular weight binder, wherein the composition provides sustained rate of methazolamide release in an in vitro drug release profile. A filler and a lubricant may also be included.

Abstract: A pharmaceutical composition has a blend of at least first and second components and a medicament in a sufficient amount to be therapeutic where the first component is selected from hydroxypropylcellulose (HPC), ethylcellulose (EC), or derivatives of HPC, EC, and hydroxyethylcellulose (HEC) and the second component is at least one other polymer. When HPC is the first component, hydroxypropylmethylcellulose (HPMC), HEC, or carboxymethylcellulose will not be the second component and when EC is the first component, HPMC will not be the second component. The medicament can be a variety of drugs or nutritional supplements. The pharmaceutical composition releases the medicament for a prolonged or sustained period of time and can be formulated into many dosage forms.

Abstract: The present invention relates to a silicone gel comprising a volatile liquid, a silicone polymer, and salicylic acid; compositions comprising the silicone gel; and methods of using such gel and composition for the prevention and treatment of acne or seborrhea.

Abstract: Disclosed is a method for the therapeutic treatment of pain related to wind up in a human or animal. The method of the invention is practiced by administering to the subject an effective amount of an analgesic pharmaceutical composition which includes a NMDA receptor antagonist in an immediate release form combined with an NMDA receptor antagonist in a sustained release form. The immediate release form and sustained release forn are present in sufficient amounts to diminsh or abolish wind up.

Abstract: Provided are tablet formulations in one embodiment comprising clavulanic acid or salt thereof, amoxycillin, and trehalose. The trehalose is, for example, amorphous anhydrous trehalose. The amorphous anhydrous trehalose is present in an amount, for example, of 5 to 50%. The formulation may further comprise, for example, desiccants, such as silica gel, or lubricants.

Abstract: An analgesic controlled release dosage form containing: (a) 40-80 weight percent of an analgesic; (b) 10-30 weight percent of a pharmaceutically acceptable filler; and (c) 10-30 weight percent of a carrier base wherein the carrier base is formed from a high molecular weight hydroxypropyl methylcellulose, a water soluble binder and optionally a water insoluble binder.

Abstract: A process for preparing solid, amorphous paroxetine comprising: (A) mixing paroxetine free base or a pharmaceutically acceptable paroxetine salt with water and pharmaceutically acceptable polymer; and (B) drying to form a composition comprising amorphous paroxetine and polymer, eliminating the need for organic solvents common for the solvent process. The resultant amorphous solid paroxetine composition is free from crystalline form, and yet has good handling properties, making it suitable for pharmaceutical use in the traditional tablet dosage form.

Abstract: A composition for treating the gastrointestinal tract comprising a porous insoluble absorbent in which the pores of the insoluble absorbent are clogged by a coating material which causes the insoluble absorbent to adhere to the gastrointestinal lining. Active ingredients, including antacids, antibiotics, antibacterial agents, platelet inhibitors, antispasmodics, and soporifics, can be mixed with or absorbed into the composition.

Abstract: The present invention relates to a composition, particularly adapted to oral administration, substantially free of alkaline-reacting compounds. The composition comprises (a) a core containing an acid-labile benzimidazole active principle, where the core comprises a plurality of nuclei and the active principle mixed together and then compressed together, and where the active principle is not in the form of an alkaline salt; (b) an intermediate layer; and (c) an enteric layer; provided that omeprazole is not the benzimidazole active principle. A process for preparing the composition is also disclosed.

Abstract: There is provided a method of adhering dye to a silica. The method comprises providing a silica slurry which includes a plurality of silica particles, depositing alum in the pores of the silica particles, reacting a base with the alum to convert the alum into aluminum hydroxide resulting in treated silica particles. The treated silica particles are then filtered and washed. Thereafter, a dye is mixed with the treated silica particles. The resultant dyed silica product is resistant to dye migration.

Abstract: Metformin Hydrochloride (herein referred to as metformin HCl) that may be 98.5%-100% pure is a high dose drug capable of being directly compressed with specific excipients into tablets having desired, hardness, disintegrating ability, and acceptable dissolution characteristics. Metformin HCl is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow metformin HCl to be compressed using the direct compression method. The tablets produced provide an acceptable in-vitro dissolution profile.

Abstract: Processes for controlling pollution by: (a) devolatizing vapor phase chemical pollutants (VP's) found in effluents and other bodies and streams of gases and liquids, and (b) stabilizing substrates from which the VP's are released. The offending VP's are converted to less offensive or inoffensive materials by interaction with an appropriately formulated treating agent (VTA/C) containing a primary halogen and at least one additional ingredient selected from the following classes of constituents (optional if bromine is the primary halogen and otherwise required): oligodynamically active metals, cohalogens, adjuncts, and facilitators. The major constituent(s) may be supplied as such, or a source of the constituent may be provided. Actinic radiation can be employed to promote reactions between the VP and the VTA/C, which is often formulated as an aqueous scrubbing medium.

Abstract: The present invention provides a sustained-release metal valproate tablet which is comparatively compact and is not influenced by a meal, the sustained-release metal valproate comprising a core tablet comprising a metal valproate having on the surface a coating layer comprising light silicic acid anhydride dispersed in a mixture of ethyl cellulose and a methacrylic acid-methyl methacrylate copolymer.

Abstract: The invention relates to antifoam oral solid dosage form preparations formed from a free flowing granular composition comprising an admixture of simethicone and either one or both of granular anhydrous tribasic calcium phosphate or dibasic calcium phosphate wherein the admixture is a uniform granular composition of not more than 1000 micron particle size which is suitable for compression into a solid dosage form for oral administration.

Abstract: The present application relates to an extruded cosmetic composition, provided in the form of a soft paste, comprising, in a fatty phase, at least one compound having a high melting temperature.The invention also relates to a process for preparing the composition by extrusion.

Abstract: The present invention is concerned with a fast-dissolving tablet for oral administration comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide (1:1) and a pharmaceutically acceptable carrier, characterized in that said carrier comprises a spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25) as a diluent, and a disintegrant; and with a direct compression process of preparing such fast-dissolving tablets.

Abstract: The present invention relates to a solid pharmaceutical dosage form for oral administration, consisting essentially of(a) at least one active substance,(b) at least one filler,(c) at least one binding agent, and(d) optionally usual auxiliaries,which dosage form, however, does not contain agar;which dosage form is manufactured without applying any compression force to the mixture of the components (a), (b), (c) and (d); andwhich dosage form disintegrates when taken into the mouth within 15 seconds.

Abstract: A process for encapsulation of caplets in a capsule comprises the following steps: a. providing empty capsule parts; b. filling at least one of said capsule parts with one or more caplets; c. putting said capsule parts together; and d. treating the combined parts by cold shrinking. The solid dosage forms obtainable by such aprocess are tamper-proof in that they cannot be opened in a way to be reassembled without showing such opening process.

Abstract: The present invention is to a tablet formulation, being a medicament for oral administration for the treatment of bacterial infections, the tablet comprising a compacted mixture of 750-950 mg of amoxycillin and a quantity of clavulanate in a weight ratio of amoxycillin:clavulanate between 6:1 to 8:1 inclusive, and having a film coating of polymers which can be applied by aqueous film coating techniques.

Abstract: A pharmaceutical composition containing an extract from inflammatory tissue inoculated with vaccinia virus may be used to suppress the death of cells caused by endotoxin, and suppress excessive production of nitrogen monoxide induced by endotoxin. The extract may also be used to relieve hypotension induced by endotoxin. In sepsis and other serious bacterial infectious diseases, endotoxin (an intracellular toxin) is produced and a shock symptom is induced by its action. The extract, having an excellent inhibitory action toward endotoxin-induced toxicity, is quite useful for the treatment or the prevention of endotoxin-induced shock symptoms, sepsis and various symptoms accompanied thereby. In addition, the extract has an inhibitory action towards abnormal nitrogen monoxide production during the diseased state and, therefore, it is also useful as a therapeutic and preventive agent for diseases wherein an excessive nitrogen monoxide production occurs, such as acute hypotension.

Abstract: The present invention provides a pharmaceutical composition in the form of a bilayer tablet comprising,(a) a first discrete zone made with Formulation (A) which comprises, a therapeutically effective decongestant amount of a sympathomimetic drug, or a pharmaceutically acceptable salt thereof, in an amount of about 18% to about 39% by weight of Formulation (A), and a first carrier base material, the first carrier base material comprising a mixture of;(I) carnauba wax in an amount of about 59% to about 81% by weight of Formulation (A); and(ii) a suitable antiadherent in an amount of about 0.25% to about 2.

Abstract: Gel compositions of formic acid and a gelling agent such as fumed silica or polyacrylic acid have been prepared for controlling parasitic mites of honey bees. The gels provide slow-release capability and have been found effective against both Varroa jacobsoni and Acarapis woodi. They are advantageous in that they have improved handling characteristics and are safer than liquid formic acid, which is quite corrosive.

Abstract: The present invention includes a method for increasing meat production while reducing fat in ruminant and non-ruminant animals and for increasing egg production in poultry and milk production in ruminant animals. The method includes mixing ingredients that include 190 proof ethanol in a concentration of about 9% by weight of a food supplement with clay and a nitrogen source such as urea to form the food supplement. The food supplement for ruminant animals additionally includes a condensed distiller's soluble fraction. The mixed ingredients are added to an animal feed such as corn. The animal feed and supplement are fed to an animal at least one per day.

Abstract: The present invention is a replacement for petroleum jelly as a base for products suitable for application to the skin. It is comprised of vegetable oil and silica. The vegetable oil is preferably a canola oil and more preferably a high oleic acid/low linolenic acid canola oil. The silica is preferably untreated fumed silica powder. The vegetable oil is preferably present in the range of 50-90% and most preferably 80%. The silica is present in the range of 5-15% and most preferably 10%. Other ingredients which may be added include vitamin E, margarine or butter, starch, and sunscreen. The base of the present invention has a significantly higher melting temperature than petroleum jelly.

Abstract: A pharmaceutical composition in the form of a substantially amorphous solid solution comprising an antifungal compound of the formula I: ##STR1## wherein: X is F; and R.sub.1 is ##STR2## or an ester or ether of said compound of Formula I; and a soluble or insoluble polymer such as: povidone or crospovidone, wherein the ratio of said compound to said polymer is about 1:3 to about 1:6 is disclosed.

Abstract: The invention relates to the use of a chemical agent of organic origin for reducing or eliminating changes in waistline or for reducing or eliminating constipation due to the taking of other agents. A preferred agent is a polyvinylpyrrolidone or povidone. By virtue of the invention, changes in waistline are reduced or eliminated during the day, as well as constipation which can be generated by the taking of other agents such as clays.

Abstract: A tablet for the local and slow release of herbal medication into the oral cavity of a subject. Also provided is a method of making the tablet and a method of using the tablet. The tablet includes a pharmaceutically effective amount of a herbal medication, a polymeric matrix material such as ethyl cellulose, a release enhancer such as PEG 4000 and a filler such as lactose. The tablet is characterized by long dissolution times of up to 120 minutes.

Abstract: A compact solid gel is described containing water, that consists of water in a concentration ranging from 15% to 90%, thermoreversible polysaccharides in a concentration ranging from 0.3% to 4%, humectant compounds in a concentration ranging from 4% to 40%, and powder phase in a concentration ranging from 2% to 35%.

Abstract: An oil-free and wax-free solid or powder-based cosmetic material having beneficial oil and wax characteristics without the detrimental effects thereof. The cosmetic material comprises pigments and/or pigment extenders which are surface treated with a hydrophobidizing material to become hydrophobic. The hydrophobidized cosmetic material is admixed with oil-free and wax-free binders in an aqueous slurry and then vacuum dehydrated and dried at an elevated temperature to provide the finished cosmetic product with excellent skin "feel", adhesiveness, extendibility, payoff (i.e., pickup of the product by an applicator) and uniformity characteristic of oil-containing cosmetics but without oil and its detrimental effects.

Abstract: The subject of the invention is an aqueous suspension containing: 0.1-20% by mass beta-cypermethrin, 0-40% by mass other pesticide substance, 1-10% by mass surface active substances in total and within this, 1-5% by mass ethoxylated polyaryl-phenol-phosphate or sulfate, 0.1-25% by mass mineral and/or synthetic silicates, 0.1-1% by mass synthetic silicic acid and up to 100% by mass other auxiliary materials and water as dispersant.

Abstract: Stable topical emulsions for cosmetic/pharmaceutical purposes can be made from a two component system of a powdered ascorbic acid phase and a liquid phase, the liquid phase containing an emulsion stabilizingly effective amount of an organoclay material.